louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01653002: Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer With Mediastinal Lymph Node Involvement
Keywords: Lung cancer
EBUS-TBNA
Epigenetics
shox2 protein, human
Lead sponsor: University Hospital, Essen
Sponsor class: OTHER
Collaborators: name: Epigenomics, Inc
First posted: 2012-07-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with proven or suspcted lung cancer and enlarged mediastinal or hilar lymph nodes

Brief summary: A DNA hypermethylation of the gene locus SHOX2 can be frequently found in lung cancer tissue. The purpose of this study is to determine whether the assessment of the hypermethylation level of SHOX2 in specimens obtained by endosonographic guided bronchoscopy makes a contribution to lung cancer staging.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of lung cancer
* enlarged mediastinal or hilar lymph nodes (\>10 mm)

Exclusion Criteria:

* clinical condition which excludes general anesthesia

Primary outcomes:
measure: Diagnostic Performance of SHOX2
timeFrame: one Year
Secondary outcomes:
Other outcomes:
Locations:
city: Essen
country: Germany
facility: Ruhrlandklinik - Universitätsklinikum Essen
Study officials:
References:
Clinical trial NCT02007902: Plasma Protein Levels and Very Preterm Birth
Official title: Early Plasma Protein Levels and Neonatal Hemodynamics: a Prospective Evaluation in Very Preterm Infants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Very Preterm Infants
Keywords: Preterm baby
Total plasma protein
Albumin
Hemodynamic disturbances
Perfusion
Near Infra Red Spectroscopy (NIRS)
Ultrasound
Lead sponsor: Centre Hospitalier Universitaire de la Réunion
Sponsor class: OTHER
Collaborators: name: INSERM CIE1, Dijon, 21000, France
First posted: 2013-12-11
Enrollment: 125
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Very preterm infants with birth at less than 32 weeks of gestational age

Brief summary: The primary aim of this study is to investigate the relationship between early plasma protein levels and hemodynamics in very preterm infants during postnatal transition. Secondary aims are the following: i) to evaluate maternal and neonatal factors affecting plasma protein level at birth; ii) to evaluate the relationship between plasma protein level and albumin level on the first day of life; iii) to evaluate the association between early hypoproteinemia and neonatal mortality and morbidity in very preterm infants.


Eligibility criteria: Inclusion Criteria:

* Parents written informed consent
* Birth at less than 32 weeks of gestational age
* Birth in a III level delivery facility at Reunion Island

Exclusion Criteria:

* Major congenital abnormalities

Primary outcomes:
measure: Evidence of clinical hemodynamic disturbances defined by arterial hypotension (non-invasive measure of MAP - mmHg - pathological for gestational age) or measured at organ colour doppler, echocardiography or NIRS
timeFrame: about 6 hours after birth
Secondary outcomes:
measure: plasma protein
timeFrame: at 1 second after birth (cord blood sample)
measure: Albumin level
timeFrame: At 12 hours after birth
measure: Mortality rate
timeFrame: patients will be followed for the duration of hospital stay, that is an average of 8 weeks
Other outcomes:
Locations:
city: Saint Denis
country: France
facility: Centre Hopsitalier Universitaire de La Réunion
state: La Réunion
city: Saint Pierre
country: France
facility: Centre Hospitalier de La Réunion
state: La Réunion
Study officials:
affiliation: CHU de La Réunion -Site du GHSR
name: Silvia Iacobelli
role: PRINCIPAL_INVESTIGATOR
affiliation: CHU de La Réunion - Hôpital Félix Guyon
name: Sylvain Samperiz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06177002: SARS-CoV-2, TESTOSTERONE AND MALE FRAGILITY
Official title: SARS-CoV-2, TESTOSTERONE AND MALE FRAGILITY (PROTEGGIMI): A MULTIDIMENSIONAL RESEARCH PROJECT
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: COVID-19
Testosterone Deficiency
Infertility, Male
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2023-12-20
Enrollment: 2000
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male COVID-19 patients and male healthy individuals

Brief summary: The hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjects more exposed to infection and more prone to developing severe complications following COVID-19 infection.

Detailed description: Preliminary data suggests that male individuals are more susceptible to COVID-19 infection, at least in Western countries, and that their mortality rate is higher than female individuals. This would seem to suggest that the hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjects more exposed to infection and more prone to developing severe complications following COVID-19 infection. Another option is that COVID-19 infection could cause a condition of acute hypogonadism, following which, the exhaustion of androgenic action could act as a co-trigger of a severe or even fatal course of the disease.

Eligibility criteria: Inclusion Criteria:

Patient Cohort:

* Male patients with an age \> 18 hospitalized in the departments dedicated to the care of patients affected by COVID-19 at the San Raffaele Hospital and with:
* biological samples positive for SARS-CoV-2;
* negative test but highly suggestive clinical and radiological picture;
* patients discharged from the emergency room with biological samples positive for SARS-CoV-2;
* ability to read and sign the informed consent

Control Cohort:

* healthy donors with an age\> 18 accessing the IRCCS OSR Blood Donor Center;
* ability to read and sign the informed consent

Exclusion Criteria:

* People with an age \< 18;
* incapacity to read and sign the informed consent

Primary outcomes:
measure: Dosage of the androgenic hormonal environment in the blood of patients and healthy controls
timeFrame: Baseline
Secondary outcomes:
measure: create an international (European) registry for the management of sensitive data in epidemiological terms and pathology outcomes relating to males with confirmed COVID-19 infection and age-matched healthy controls
timeFrame: Baseline
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS Ospedale San Raffaele
state: Lombardy
Study officials:
References:
Clinical trial NCT02646202: Scleroligation for Eradication of Gastroesophageal Varices.
Official title: Scleroligation is a Safe and Effective New Technique for Eradication of Gastroesophageal Varices.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Gastroesophageal Varices
Lead sponsor: Tanta University
Sponsor class: OTHER
Collaborators: name: Tanta University
First posted: 2016-01-05
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gastric varices occur in 5-33% of patients with portal hypertension. Concomitant gastro esophageal varices are the most common type. Both endoscopic sclerotherapy and band ligation are very effective in controlling acute esophageal varices bleeding and preventing rebleeding.

Detailed description: Evaluation of a new scleroligation technique for management of bleeding gastro-esophageal varices regarding efficacy, complications, variceal recurrence, and survival.

Eligibility criteria: Inclusion Criteria:

* cirrhotic patients presenting with an acute or recent episode of gastro-esophageal variceal bleeding.

Exclusion Criteria:

* Patients were excluded if they had malignancy of any origin.
* Any terminal illness, such as heart failure, uremia, or chronic pulmonary diseases.
* Other potential causes of GIT bleeding.
* Patients with previous endoscopic or surgical intervention for varices were also excluded.

Primary outcomes:
measure: Number of sessions to complete variceal obliteration
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tropical medicine dept.-Tanta university hospital
Study officials:
affiliation: Head of endoscopy unit - Tropical medicine department- Tanta
name: Ferial El-kalla, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: liver diseases dept.- Tanta university hospital
name: Mohamed Elhendawy, Consultant
role: PRINCIPAL_INVESTIGATOR
affiliation: liver diseases dept.-Tanta university hospital
name: Loai Mansour, Consultant
role: STUDY_DIRECTOR
affiliation: liver diseases dept.-Tanta university hospital
name: Abdelrahman kobtan, Consultant
role: STUDY_CHAIR
affiliation: liver diseases dept.-Tanta university hospital
name: Rehab Badawy, Consultant
role: STUDY_CHAIR
affiliation: liver diseases dept.-Tanta university hospital
name: Hanan Elbasat, Professor
role: STUDY_CHAIR
affiliation: Liver diseases and gastroenterology dept.-Tanta university hospital
name: Sherief Abd-Elsalam, Consultant
role: STUDY_CHAIR
References:
citation: Mansour L, El-Kalla F, El-Bassat H, Abd-Elsalam S, El-Bedewy M, Kobtan A, Badawi R, Elhendawy M. Randomized controlled trial of scleroligation versus band ligation alone for eradication of gastroesophageal varices. Gastrointest Endosc. 2017 Aug;86(2):307-315. doi: 10.1016/j.gie.2016.12.026. Epub 2017 Jan 9.
Clinical trial NCT04497402: Sex-Informed Data in the COVID-19 Pandemic.
Official title: Sex-Informed Data in the COVID-19 Pandemic.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Keywords: sex
gender
thrombosis
immunity
gut microbiota
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with laboratory confirmed SARS-Cov-2 infection (positive for real-time reverse-transcriptase polymerase-chain reaction assay for pharyngeal swab specimens) of any severity (from asymptomatic to severe manifestations).

Brief summary: Sex and gender matter to health equity, especially in a pandemic. Sex (a biological attribute) and gender (a social construct) may influence an individual's susceptibility, vulnerability and exposure to infectious disease. In previous coronavirus epidemics (SARS and MERS), male sex was associated with worse outcomes. Both immune and the hemostatic response display ample sexual dimorphism.

The primary aim of the study is to determine whether sex differences in biomarkers of platelet and immune function, gut microbiome, clinical characteristics, therapy, clinical cost sensitive outcomes (i.e. in-hospital transition of care, case severity, and mortality due to COVID-19) exist in patients affected by COVID-19.


Eligibility criteria: Inclusion Criteria:

* Patients with laboratory confirmed SARS-Cov-2 infection of any severity.

Exclusion Criteria:

* Pregnancy.
* Younger than 18 years of age.

Primary outcomes:
measure: Sex differences in platelet and immune function and COVID19 severity
timeFrame: 3 months
Secondary outcomes:
measure: Gut microbiome and COVID19 severity
timeFrame: 3 months
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Sapienza University of Rome - Policlinico Umberto I Roma
Study officials:
References:
Clinical trial NCT01556802: Use of Minocicline in Patients With Stroke
Official title: Effect of Minocicline Use in Less Neurologic Sequels in Patients With Stroke
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Stroke
Brain Ischemia
Paralysis
Keywords: stroke
sequelaes
minocicline
Lead sponsor: Hospital Universitario Hernando Moncaleano Perdomo
Sponsor class: OTHER
First posted: 2012-03-16
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators will evaluate the National Institute of Health Stroke Scale/Score (NIHSS)in patients with stroke, and then give Minocycline 100mg po every 12 hours or placebo for five days, then perform periodic evaluations to determine the status and degree of neurological sequelae developed.


Eligibility criteria: Inclusion Criteria:

* NIHSS scale greater than 5
* Onset of symptoms less than 24 hours
* normal Cranial Tomography(CT)
* CT evidence of cerebral ischemia
* Acceptance of study entry

Exclusion Criteria:

* Hemorrhagic cerebrovascular disease
* Other neurological diseases
* Concomitant structural damage
* History of neurosurgery
* Known allergy to tetracyclines
* Concomitant infectious diseases requiring antibiotic treatment.
* History of Stroke
* Women pregnant or breast-feeding

Primary outcomes:
measure: To determine the efficacy of minocycline in reducing neurological sequelae in patients with stroke
timeFrame: one year
Secondary outcomes:
measure: Identify the side effects of the intervention administered during the treatment time and 30 days later.
timeFrame: one year
Other outcomes:
Locations:
city: Neiva
country: Colombia
facility: University Hospital hernando Moncaleano Perdomo
state: Huila
Study officials:
affiliation: Universidad Surcolombiana
name: Nataly Bedoya, Internist
role: STUDY_DIRECTOR
affiliation: Universidad Surcolombiana
name: Hernan Vargas, Internist
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidad Surcolombiana
name: Hugo Osorio, Internist
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidad Surcolombiana
name: Guillermo Gonzalez, Neurologist
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidad Surcolombiana
name: Javier Saldaña, Epidemiology
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital Hernando Moncaleano Perdomo
name: Efrain Amaya, Neurologist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01972802: International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study
Official title: International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Evaluate the Association Between Certain Environmental Exposures (e.g. Cigarette Smoking, Alcohol Drinking, Betel Nut Chewing…) and Head and Neck Cancers
Assess the Effect of Genetic Factors, Including Both SNP and Copy Number Variation (CNV) Through Analysis of Both Main Effect and Gene-gene Interaction
Keywords: HEAD AND NECK
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-10-30
Enrollment: 900
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: NTUH HEAD AND NECK PATIENT AND CONTROLS

Brief summary: Our overall objective is to understand the role of lifestyle factors, genetics and HPV infection in the development and prognosis of head and neck cancer particularly in Asia.


Eligibility criteria: Inclusion Criteria:

Age 18\~80 Incident head and neck cancer patients

* Oral, oropharynx and hypopharynx (C00-C14)
* Laryngreal cancer (C32)
* \*Esophageal cancer if possible (C15)

Exclusion Criteria:

* Salivary gland (C07-C08)
* Nasopharynx (C11)
* Thyroid (C79.3)

Primary outcomes:
measure: head and neck cancer risk factor
timeFrame: Four years
Secondary outcomes:
Other outcomes:
Locations:
city: Tiapei
country: Taiwan
facility: National Taiwan University Hospital
state: Taipei
Study officials:
affiliation: National Taiwan University Hospital
name: Pei-Jen Lou
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01135602: Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study
Official title: Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Alcohol Dependence
Keywords: Alcohol dependence
Alcoholism
Topiramate
Lead sponsor: Chiang Mai University
Sponsor class: OTHER
First posted: 2010-06-03
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 12-week, open-label study of topiramate in hospitalized patients with alcoholism


Eligibility criteria: Inclusion Criteria:

* Patients hospitalized due to alcohol-related problems
* DSM-IV-TR alcohol dependence
* \>/= 35 drinks/week (male) or \>/= 28 drinks/week (female) for \>/= 1 week during four weeks prior to the admission
* AUDIT score \>/= 8
* Mild or no alcohol withdrawal
* Body mass index \> 18 kg/m2
* No pregnancy and no plan for pregnancy (female)
* Intention to decrease or stop drinking

Exclusion Criteria:

* Severe psychiatric and cognitive disorders
* Other substance dependence, except nicotine and caffeine dependence, during 6 months prior to enrollment
* Taking antipsychotics, mood stabilizers, anticonvulsants, opioid analgesics, systematic steroids, carbonic anhydrase inhibitors, hydrochlorthiazide, metformin, pioglitazone, or disulfiram
* Moderate to high risk of suicide
* Medical history of narrow angle glaucoma, renal impairment, kidney stones, and seizures
* Unstable medical conditions
* Plan to receive a formal treatment for alcoholism from other treatment settings
* Under legal process
* Pregnancy and nursing woman
* Abnormal laboratory tests, including blood urea nitrogen, creatinine, electrolytes, and fasting blood sugar

Primary outcomes:
measure: Cognition
timeFrame: 12 weeks
Secondary outcomes:
measure: Alcohol drink/day
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Muang
country: Thailand
facility: Maharaj Nakorn Chiang Mai Hospital
state: Chiang Mai
city: Muang
country: Thailand
facility: Maharaj Nakorn Chiang Mai Hospital
state: Chiang Mai
Study officials:
affiliation: Department of Psychiatry, Faculty of Medicine, Chiang Mai University
name: Manit Srisurapanont, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04773002: A Comparison of Volatile Anesthesia and Total Intravenous Anesthesia (TIVA)
Official title: A Comparison of Volatile Anesthesia and Total Intravenous Anesthesia (TIVA) on Ecchymosis, Edema, and Intraoperative Bleeding in Rhinoplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rhinoplasty
Ecchymosis
Edema
Hemorrhage
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2021-02-26
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Rhinoplasty patients

Brief summary: In this study, investigators wanted to investigate the effect of volatile anesthesia and total intravenous anesthesia (TIVA) on ecchymosis, edema, and intraoperative bleeding in rhinoplasty.

Detailed description: Routine monitorization (blood pressure, pulse, oxygen saturation with pulse oximetry and electrocardiogram) will be applied to all patients taken into the operation room.

In Group P (TIVA), induction of anesthesia will be achieved with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 μ / kg fentanyl. Propofol and remifentanil will be used in the continuation of anesthesia.

In Group S (Volatile), anesthesia will be induced with 2 mg / kg propofol, 0.6 mg / kg rocuronium and 1 μ / kg fentanyl. 50% nitrous oxide + 50% oxygen and 2% sevoflurane will be used in the continuation of anesthesia.

All patients will receive 2 ml/kg/hour Ringer's lactate solution during the operation.

Eligibility criteria: Inclusion Criteria:

* Between 18 and 65 years
* Planned to rhinoplasty
* An American Society of Anesthesiologists score of 1 or 2

Exclusion Criteria:

* Steroid use
* Patients with coagulation disorders, •Rejected to participation

Primary outcomes:
measure: Edema and ecchymosis in rhinoplasty according to the type of anesthesia.
timeFrame: one time in six months
Secondary outcomes:
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Gaziosmanpasa University
Study officials:
affiliation: Gaziosmanpasa university
name: Muzaffer Katar
role: STUDY_CHAIR
References:
Clinical trial NCT05538702: Acute Oral Effects of Heated Tobacco Products
Official title: Acute Oral Effects of Heated Tobacco Products Compared to Traditional Cigarettes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nicotine Dependence, Cigarettes
Keywords: nicotine
heated tobacco product
blood flow
cigarette
Lead sponsor: Semmelweis University
Sponsor class: OTHER
First posted: 2022-09-14
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Heated tobacco products (HTP) are devices which heat, but not burn tobacco. They do not produce cigarette smoke but rather an aerosol. HTPs are marketed as less harmful alternatives to smoking. Use and awareness of these devices have grown exponentially in recent years, with probably millions of people currently using them. There is very little literature about them, so it is quite important to study the effects caused on the human body by these products.

The benefits and risks of HTP use are uncertain. There is no research on the acute oral effects of HTPs in the scientific literature.

Detailed description: Measurements of acute oral effects before and after using HTP with bland flavour (HEETS Bronze Selection), with methol flavour (HEETS Blue Selection), conventional cigarette and placebo device:

measurement of exhaled CO changes by Smokerlyzer piCO measurement of oral mucosal blood flow changes by Perilam PSI System High Resolution (LASCA method) measurement of blood pressure and pulse by an automatic blood pressure monitor (Omron M2, Omron Healthcare Inc., Kyoto, Japan)

Eligibility criteria: Inclusion Criteria:

* age: 18-49 years
* signed consent form
* smoking regularly heated tobacco product and/or conventional cigarette for \> half year

Exclusion Criteria:

* not pregnant and not planning pregnancy in the next 6 month BMI index \< 30
* no severe parodontal disease
* no acute illness in the last 2 weeks
* no chronic disease (eg.: diabetes)

Primary outcomes:
measure: Change from baseline in blood flow after smoking
timeFrame: baseline, immediately after smoking, and 15 minutes after smoking
Secondary outcomes:
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Semmelweis University, Department of Prosthodontics
Study officials:
References: